-
1
-
-
34548244153
-
Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression
-
17530287 10.1007/s00432-007-0220-2 1:CAS:528:DC%2BD2sXpsFehur4%3D
-
Alldinger I, Schaefer KL, Goedde D, Ottaviano L, Dirksen U, Ranft A, Juergens H, Gabbert HE, Knoefel WT, Poremba C (2007) Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J Cancer Res Clin Oncol 133(10):749-759
-
(2007)
J Cancer Res Clin Oncol
, vol.133
, Issue.10
, pp. 749-759
-
-
Alldinger, I.1
Schaefer, K.L.2
Goedde, D.3
Ottaviano, L.4
Dirksen, U.5
Ranft, A.6
Juergens, H.7
Gabbert, H.E.8
Knoefel, W.T.9
Poremba, C.10
-
2
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
18316791 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D
-
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-1634
-
(2008)
J Clin Oncol
, vol.26
, Issue.10
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
Juan, T.7
Sikorski, R.8
Suggs, S.9
Radinsky, R.10
Patterson, S.D.11
Chang, D.D.12
-
3
-
-
0035444798
-
Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study
-
11531254 10.1054/bjoc.2001.1964 1:CAS:528:DC%2BD3MXns1yktr8%3D
-
Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85(5):692-696
-
(2001)
Br J Cancer
, vol.85
, Issue.5
, pp. 692-696
-
-
Andreyev, H.J.1
Norman, A.R.2
Cunningham, D.3
Oates, J.4
Dix, B.R.5
Iacopetta, B.J.6
Young, J.7
Walsh, T.8
Ward, R.9
Hawkins, N.10
Beranek, M.11
Jandik, P.12
Benamouzig, R.13
Jullian, E.14
Laurent-Puig, P.15
Olschwang, S.16
Muller, O.17
Hoffmann, I.18
Rabes, H.M.19
Zietz, C.20
Troungos, C.21
Valavanis, C.22
Yuen, S.T.23
Ho, J.W.24
Croke, C.T.25
O'Donoghue, D.P.26
Giaretti, W.27
Rapallo, A.28
Russo, A.29
Bazan, V.30
Tanaka, M.31
Omura, K.32
Azuma, T.33
Ohkusa, T.34
Fujimori, T.35
Ono, Y.36
Pauly, M.37
Faber, C.38
Glaesener, R.39
De Goeij, A.F.40
Arends, J.W.41
Andersen, S.N.42
Lovig, T.43
Breivik, J.44
Gaudernack, G.45
Clausen, O.P.46
De Angelis, P.D.47
Meling, G.I.48
Rognum, T.O.49
Smith, R.50
Goh, H.S.51
Font, A.52
Rosell, R.53
Sun, X.F.54
Zhang, H.55
Benhattar, J.56
Losi, L.57
Lee, J.Q.58
Wang, S.T.59
Clarke, P.A.60
Bell, S.61
Quirke, P.62
Bubb, V.J.63
Piris, J.64
Cruickshank, N.R.65
Morton, D.66
Fox, J.C.67
Al-Mulla, F.68
Lees, N.69
Hall, C.N.70
Snary, D.71
Wilkinson, K.72
Dillon, D.73
Costa, J.74
Pricolo, V.E.75
Finkelstein, S.D.76
Thebo, J.S.77
Senagore, A.J.78
Halter, S.A.79
Wadler, S.80
Malik, S.81
Krtolica, K.82
Urosevic, N.83
more..
-
4
-
-
3042785708
-
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections
-
15208356 10.1369/jhc.3A6195.2004 1:CAS:528:DC%2BD2cXls1alurk%3D
-
Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7):893-901
-
(2004)
J Histochem Cytochem
, vol.52
, Issue.7
, pp. 893-901
-
-
Atkins, D.1
Reiffen, K.A.2
Tegtmeier, C.L.3
Winther, H.4
Bonato, M.S.5
Storkel, S.6
-
5
-
-
76049098292
-
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases
-
20103678 10.1158/1078-0432.CCR-09-2446 1:CAS:528:DC%2BC3cXhs1aqsr4%3D
-
Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790-799
-
(2010)
Clin Cancer Res
, vol.16
, Issue.3
, pp. 790-799
-
-
Baldus, S.E.1
Schaefer, K.L.2
Engers, R.3
Hartleb, D.4
Stoecklein, N.H.5
Gabbert, H.E.6
-
6
-
-
0023068346
-
Ras genes
-
3304147 10.1146/annurev.bi.56.070187.004023 1:CAS:528:DyaL2sXkslWlurY%3D
-
Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779-827
-
(1987)
Annu Rev Biochem
, vol.56
, pp. 779-827
-
-
Barbacid, M.1
-
7
-
-
77949435827
-
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
-
20100961 10.1200/JCO.2009.24.6116 1:CAS:528:DC%2BC3cXktF2ltbk%3D
-
Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28(7):1254-1261
-
(2010)
J Clin Oncol
, vol.28
, Issue.7
, pp. 1254-1261
-
-
Bardelli, A.1
Siena, S.2
-
8
-
-
34047248571
-
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
-
17363584 10.1158/0008-5472.CAN-06-4158 1:CAS:528:DC%2BD2sXivV2ns7w%3D
-
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67(6):2643-2648
-
(2007)
Cancer Res
, vol.67
, Issue.6
, pp. 2643-2648
-
-
Benvenuti, S.1
Sartore-Bianchi, A.2
Di Nicolantonio, F.3
Zanon, C.4
Moroni, M.5
Veronese, S.6
Siena, S.7
Bardelli, A.8
-
9
-
-
33748533501
-
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
-
16865406 10.1007/s00428-006-0247-9 1:CAS:528:DC%2BD28XptF2kt7k%3D
-
Bibeau F, Boissiere-Michot F, Sabourin JC, Gourgou-Bourgade S, Radal M, Penault-Llorca F, Rochaix P, Arnould L, Bralet MP, Azria D, Ychou M (2006) Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch 449(3):281-287
-
(2006)
Virchows Arch
, vol.449
, Issue.3
, pp. 281-287
-
-
Bibeau, F.1
Boissiere-Michot, F.2
Sabourin, J.C.3
Gourgou-Bourgade, S.4
Radal, M.5
Penault-Llorca, F.6
Rochaix, P.7
Arnould, L.8
Bralet, M.P.9
Azria, D.10
Ychou, M.11
-
10
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
15677699 10.1200/JCO.2005.08.037 1:CAS:528:DC%2BD2MXjt1Ckuro%3D
-
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23(9):1803-1810
-
(2005)
J Clin Oncol
, vol.23
, Issue.9
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
Shah, M.4
Schwartz, G.K.5
Tse, A.6
Hamilton, A.7
Pan, D.8
Schrag, D.9
Schwartz, L.10
Klimstra, D.S.11
Fridman, D.12
Kelsen, D.P.13
Saltz, L.B.14
-
11
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
20978259 10.1001/jama.2010.1535
-
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16):1812-1820
-
(2010)
JAMA
, vol.304
, Issue.16
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
Sartore-Bianchi, A.4
Tu, D.5
Siena, S.6
Lamba, S.7
Arena, S.8
Frattini, M.9
Piessevaux, H.10
Van Cutsem, E.11
O'Callaghan, C.J.12
Khambata-Ford, S.13
Zalcberg, J.R.14
Simes, J.15
Karapetis, C.S.16
Bardelli, A.17
Tejpar, S.18
-
12
-
-
34247278727
-
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
-
10.1038/sj.bjc.6603685 17375050 10.1038/sj.bjc.6603685
-
Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96(8):1166-1169. doi: 10.1038/sj.bjc.6603685
-
(2007)
Br J Cancer
, vol.96
, Issue.8
, pp. 1166-1169
-
-
Di Fiore, F.1
Blanchard, F.2
Charbonnier, F.3
Le Pessot, F.4
Lamy, A.5
Galais, M.P.6
Bastit, L.7
Killian, A.8
Sesboue, R.9
Tuech, J.J.10
Queuniet, A.M.11
Paillot, B.12
Sabourin, J.C.13
Michot, F.14
Michel, P.15
Frebourg, T.16
-
13
-
-
33751165545
-
Recurrent KRAS codon 146 mutations in human colorectal cancer
-
16969076 10.4161/cbt.5.8.3251 1:CAS:528:DC%2BD28XhtlCgtbbE
-
Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5(8):928-932
-
(2006)
Cancer Biol Ther
, vol.5
, Issue.8
, pp. 928-932
-
-
Edkins, S.1
O'Meara, S.2
Parker, A.3
Stevens, C.4
Reis, M.5
Jones, S.6
Greenman, C.7
Davies, H.8
Dalgliesh, G.9
Forbes, S.10
Hunter, C.11
Smith, R.12
Stephens, P.13
Goldstraw, P.14
Nicholson, A.15
Chan, T.L.16
Velculescu, V.E.17
Yuen, S.T.18
Leung, S.Y.19
Stratton, M.R.20
Futreal, P.A.21
more..
-
14
-
-
0027209054
-
Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis
-
8489386 10.1001/archsurg.1993.01420170056008 1:STN:280: DyaK3s3ls1Onug%3D%3D discussion 531-522
-
Finkelstein SD, Sayegh R, Bakker A, Swalsky P (1993) Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128(5):526-531 discussion 531-522
-
(1993)
Arch Surg
, vol.128
, Issue.5
, pp. 526-531
-
-
Finkelstein, S.D.1
Sayegh, R.2
Bakker, A.3
Swalsky, P.4
-
15
-
-
0034548712
-
K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression
-
11118062 1:CAS:528:DC%2BD3cXosl2it7o%3D
-
Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R (2000) K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60(23):6750-6756
-
(2000)
Cancer Res
, vol.60
, Issue.23
, pp. 6750-6756
-
-
Guerrero, S.1
Casanova, I.2
Farre, L.3
Mazo, A.4
Capella, G.5
Mangues, R.6
-
16
-
-
10744232660
-
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors
-
14678966 1:CAS:528:DC%2BD3sXpvVagsbk%3D
-
Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M (2003) Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63(23):8132-8137
-
(2003)
Cancer Res
, vol.63
, Issue.23
, pp. 8132-8137
-
-
Ikenoue, T.1
Hikiba, Y.2
Kanai, F.3
Tanaka, Y.4
Imamura, J.5
Imamura, T.6
Ohta, M.7
Ijichi, H.8
Tateishi, K.9
Kawakami, T.10
Aragaki, J.11
Matsumura, M.12
Kawabe, T.13
Omata, M.14
-
17
-
-
24044460118
-
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: Biological and clinical implications
-
15980160 10.1093/annonc/mdi282 1:STN:280:DC%2BD2MrjtlGhtg%3D%3D
-
Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D, Gugenheim J, Michiels JF (2005) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 16(9):1503-1507
-
(2005)
Ann Oncol
, vol.16
, Issue.9
, pp. 1503-1507
-
-
Italiano, A.1
Saint-Paul, M.C.2
Caroli-Bosc, F.X.3
Francois, E.4
Bourgeon, A.5
Benchimol, D.6
Gugenheim, J.7
Michiels, J.F.8
-
19
-
-
40949135397
-
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
-
18339877 10.1158/0008-5472.CAN-07-5659 1:CAS:528:DC%2BD1cXjtFOhtro%3D
-
Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953-1961
-
(2008)
Cancer Res
, vol.68
, Issue.6
, pp. 1953-1961
-
-
Jhawer, M.1
Goel, S.2
Wilson, A.J.3
Montagna, C.4
Ling, Y.H.5
Byun, D.S.6
Nasser, S.7
Arango, D.8
Shin, J.9
Klampfer, L.10
Augenlicht, L.H.11
Perez-Soler, R.12
Mariadason, J.M.13
-
20
-
-
34548238762
-
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
-
17664471 10.1200/JCO.2006.10.5437 1:CAS:528:DC%2BD2sXhtVWqs7rF
-
Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230-3237
-
(2007)
J Clin Oncol
, vol.25
, Issue.22
, pp. 3230-3237
-
-
Khambata-Ford, S.1
Garrett, C.R.2
Meropol, N.J.3
Basik, M.4
Harbison, C.T.5
Wu, S.6
Wong, T.W.7
Huang, X.8
Takimoto, C.H.9
Godwin, A.K.10
Tan, B.R.11
Krishnamurthi, S.S.12
Burris Iii., H.A.13
Poplin, E.A.14
Hidalgo, M.15
Baselga, J.16
Clark, E.A.17
Mauro, D.J.18
-
21
-
-
33750615769
-
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
-
17050875 10.1200/JCO.2006.06.7595 1:CAS:528:DC%2BD28Xht1eiu73K
-
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24(30):4914-4921
-
(2006)
J Clin Oncol
, vol.24
, Issue.30
, pp. 4914-4921
-
-
Lenz, H.J.1
Van Cutsem, E.2
Khambata-Ford, S.3
Mayer, R.J.4
Gold, P.5
Stella, P.6
Mirtsching, B.7
Cohn, A.L.8
Pippas, A.W.9
Azarnia, N.10
Tsuchihashi, Z.11
Mauro, D.J.12
Rowinsky, E.K.13
-
22
-
-
38649099966
-
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
-
18202412 10.1200/JCO.2007.12.5906 1:CAS:528:DC%2BD1cXitVGntLc%3D
-
Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374-379
-
(2008)
J Clin Oncol
, vol.26
, Issue.3
, pp. 374-379
-
-
Lievre, A.1
Bachet, J.B.2
Boige, V.3
Cayre, A.4
Le Corre, D.5
Buc, E.6
Ychou, M.7
Bouche, O.8
Landi, B.9
Louvet, C.10
Andre, T.11
Bibeau, F.12
Diebold, M.D.13
Rougier, P.14
Ducreux, M.15
Tomasic, G.16
Emile, J.F.17
Penault-Llorca, F.18
Laurent-Puig, P.19
-
23
-
-
52749099497
-
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
-
18804418 10.1016/S1470-2045(08)70206-7 1:CAS:528:DC%2BD1cXhtFOmurvJ
-
Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962-972
-
(2008)
Lancet Oncol
, vol.9
, Issue.10
, pp. 962-972
-
-
Linardou, H.1
Dahabreh, I.J.2
Kanaloupiti, D.3
Siannis, F.4
Bafaloukos, D.5
Kosmidis, P.6
Papadimitriou, C.A.7
Murray, S.8
-
24
-
-
37349063195
-
Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer
-
10.1001/archotol.133.12.1277
-
Lopez-Albaitero A, Ferris RL (2007) Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otollanyngol Head Neck Surg 133:1277-1281
-
(2007)
Arch Otollanyngol Head Neck Surg
, vol.133
, pp. 1277-1281
-
-
Lopez-Albaitero, A.1
Ferris, R.L.2
-
25
-
-
68749119351
-
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
-
19603018 10.1038/sj.bjc.6605177 1:CAS:528:DC%2BD1MXpvFyisb0%3D
-
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101(4):715-721
-
(2009)
Br J Cancer
, vol.101
, Issue.4
, pp. 715-721
-
-
Loupakis, F.1
Ruzzo, A.2
Cremolini, C.3
Vincenzi, B.4
Salvatore, L.5
Santini, D.6
Masi, G.7
Stasi, I.8
Canestrari, E.9
Rulli, E.10
Floriani, I.11
Bencardino, K.12
Galluccio, N.13
Catalano, V.14
Tonini, G.15
Magnani, M.16
Fontanini, G.17
Basolo, F.18
Falcone, A.19
Graziano, F.20
more..
-
26
-
-
70450195266
-
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
-
19636327 10.1038/nrclinonc.2009.111 1:CAS:528:DC%2BD1MXhtVKjsrjO
-
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6(9):519-527
-
(2009)
Nat Rev Clin Oncol
, vol.6
, Issue.9
, pp. 519-527
-
-
Normanno, N.1
Tejpar, S.2
Morgillo, F.3
De Luca, A.4
Van Cutsem, E.5
Ciardiello, F.6
-
27
-
-
74949090294
-
Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort
-
19787792 10.1002/gcc.20717 1:CAS:528:DC%2BD1MXhsVWht7zJ
-
Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosom Cancer 49(1):40-51
-
(2010)
Genes Chromosom Cancer
, vol.49
, Issue.1
, pp. 40-51
-
-
Ottaviano, L.1
Schaefer, K.L.2
Gajewski, M.3
Huckenbeck, W.4
Baldus, S.5
Rogel, U.6
MacKintosh, C.7
De Alava, E.8
Myklebost, O.9
Kresse, S.H.10
Meza-Zepeda, L.A.11
Serra, M.12
Cleton-Jansen, A.M.13
Hogendoorn, P.C.14
Buerger, H.15
Aigner, T.16
Gabbert, H.E.17
Poremba, C.18
-
28
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
29
-
-
84872604206
-
Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab)
-
abstr 383
-
Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams RT et al. (2012) Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). J Clin Oncol 30(suppl); abstr 383
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Peeters, M.1
Douillard, J.Y.2
Van Cutsem, E.3
Siena, S.4
Zhang, K.5
Williams, R.T.6
-
30
-
-
33745959940
-
Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue
-
16867224 10.1593/neo.06238 1:CAS:528:DC%2BD28XovVKkt7o%3D
-
Schaefer KL, Brachwitz K, Braun Y, Diallo R, Wai DH, Zahn S, Schneider DT, Kuhnen C, Vollmann A, Brockhoff G, Gabbert HE, Poremba C (2006) Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia 8(7):613-622
-
(2006)
Neoplasia
, vol.8
, Issue.7
, pp. 613-622
-
-
Schaefer, K.L.1
Brachwitz, K.2
Braun, Y.3
Diallo, R.4
Wai, D.H.5
Zahn, S.6
Schneider, D.T.7
Kuhnen, C.8
Vollmann, A.9
Brockhoff, G.10
Gabbert, H.E.11
Poremba, C.12
-
31
-
-
70349939382
-
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
-
19738166 10.1093/jnci/djp280 1:CAS:528:DC%2BD1MXht1Ojt73I
-
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19):1308-1324
-
(2009)
J Natl Cancer Inst
, vol.101
, Issue.19
, pp. 1308-1324
-
-
Siena, S.1
Sartore-Bianchi, A.2
Di Nicolantonio, F.3
Balfour, J.4
Bardelli, A.5
-
32
-
-
77949888718
-
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma
-
20130434 10.1159/000258498 1:CAS:528:DC%2BC3cXhsFCqsrs%3D
-
Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E, Colucci G (2009) The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. Oncology 77(Suppl 1):69-74
-
(2009)
Oncology
, vol.77
, Issue.SUPPL. 1
, pp. 69-74
-
-
Silvestris, N.1
Tommasi, S.2
Petriella, D.3
Santini, D.4
Fistola, E.5
Russo, A.6
Numico, G.7
Tonini, G.8
Maiello, E.9
Colucci, G.10
-
33
-
-
77951711694
-
Prognostic and predictive biomarkers in resected colon cancer: Current status and future perspectives for integrating genomics into biomarker discovery
-
20350999 10.1634/theoncologist.2009-0233 1:CAS:528:DC%2BC3cXmsFynsLo%3D
-
Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15(4):390-404
-
(2010)
Oncologist
, vol.15
, Issue.4
, pp. 390-404
-
-
Tejpar, S.1
Bertagnolli, M.2
Bosman, F.3
Lenz, H.J.4
Garraway, L.5
Waldman, F.6
Warren, R.7
Bild, A.8
Collins-Brennan, D.9
Hahn, H.10
Harkin, D.P.11
Kennedy, R.12
Ilyas, M.13
Morreau, H.14
Proutski, V.15
Swanton, C.16
Tomlinson, I.17
Delorenzi, M.18
Fiocca, R.19
Van Cutsem, E.20
Roth, A.21
more..
-
34
-
-
84867117207
-
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
-
10.1200/JCO.2012.42.2592
-
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. doi: 10.1200/JCO.2012.42.2592
-
(2012)
J Clin Oncol
-
-
Tejpar, S.1
Celik, I.2
Schlichting, M.3
Sartorius, U.4
Bokemeyer, C.5
Van Cutsem, E.6
-
35
-
-
77954215850
-
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
-
20413299 10.1016/j.ejca.2010.03.036 1:CAS:528:DC%2BC3cXosVKjsbw%3D
-
Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46(11):1997-2009
-
(2010)
Eur J Cancer
, vol.46
, Issue.11
, pp. 1997-2009
-
-
Tol, J.1
Dijkstra, J.R.2
Klomp, M.3
Teerenstra, S.4
Dommerholt, M.5
Vink-Borger, M.E.6
Van Cleef, P.H.7
Van Krieken, J.H.8
Punt, C.J.9
Nagtegaal, I.D.10
-
36
-
-
0035117355
-
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
-
11255078 10.1016/S1040-8428(00)00134-7 1:STN:280:DC%2BD3MrgsVCrsg%3D%3D
-
Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38(1):17-23
-
(2001)
Crit Rev Oncol Hematol
, vol.38
, Issue.1
, pp. 17-23
-
-
Yang, X.D.1
Jia, X.C.2
Corvalan, J.R.3
Wang, P.4
Davis, C.G.5
|